Active substanceDexamethasone + TobramycinDexamethasone + Tobramycin
Similar drugsTo uncover
  • DexaTeach
    drops d / eye 
    ROMFARMA, OOO     Russia
  • Tebridex®
    drops d / eye 
  • Tebridex®
    ointment d / eye 
  • Tebronez
    drops d / eye 
  • Dosage form: & nbspeye drops
    Composition:

    1 ml of the solution contains:

    active substances: tobramycin sulfate, tobramycin equivalent 3.0 mg, dexamethasone sodium phosphate, dexamethasone equivalent 1, 0 mg;

    Excipients: benzalkonium chloride, disodium EDTA, disodium hydrogen phosphate dihydrate, sodium metabisulphite, sodium chloride, creatine, propylene glycol, purified water, sodium hydroxide *), sulfuric acid *).

    *) to adjust the pH
    Description:Transparent solution from colorless to slightly yellow in color.
    Pharmacotherapeutic group:glucocorticosteroid for topical use + antibiotic-aminoglycoside
    ATX: & nbsp

    S.01.C.A   Corticosteroids in combination with antimicrobials

    S.01.C.A.01   Dexamethasone in combination with antimicrobials

    Pharmacodynamics:

    Combined drug, has the properties of its active components - antibiotic and glucocorticosteroid.

    Tobramycin - antibacterial agent from the group of aminoglycosides (2nd generation). Suppress the growth and development of gram-negative and gram-positive microorganisms. Blocks the 30-S subunit in the ribosome and stops the synthesis of the protein. At higher concentrations, it disrupts the function of cytoplasmic membranes, causing cell death.

    The drug is active against gram-positive bacteria (staphylococci - Staphylococcus aureus, Staphylococcus epidermidis, Citrobacter Species, Enterobacter Species) and Gram-negative bacteria (Escherichia coli, Klebsiella Species, Morganella Morganii, Pseudomonas aeruginosa, Proteus mirabili, Proteus vulgaris, Providensia spp, Serratia spp).

    Dexamethasone - fluorinated glucocorticosteroid, which has a pronounced anti-inflammatory, antiallergic and immunosuppressive action. When applied locally, it removes itching and constricts vessels. Interacts with specific cytoplasmic receptors and forms a complex penetrating the nucleus of the cell, and stimulating the synthesis of mRNA. Prevents the release of inflammatory mediators from eosinophils and mast cells. It inhibits the activity of hyaluronidase, collagenase and proteases. Reduces the permeability of capillaries, stabilizes cell membranes.

    Pharmacokinetics:

    With topical application, systemic absorption is low.

    Indications:

    The drug Tebrizone is prescribed for the treatment of infectious diseases of the eyes and paraorbital area caused by microorganisms sensitive to the preparation:

    - blepharitis, conjunctivitis, blepharoconjunctivitis;

    - keratitis (without damage to the epithelium);

    - prevention of postoperative infections.

    Contraindications:

    - Individual hypersensitivity to the components of the drug.

    - viral diseases of the cornea and conjunctiva (including keratitis caused by Herpes simplex, chickenpox);

    - tuberculosis of the eye;

    - fungal diseases of the eyes;

    - condition after removal of the foreign body of the cornea.

    Pregnancy and lactation:

    Sufficient experience in the use of the drug during pregnancy, breast-feeding and in children there. It is possible to use Teborazone for the treatment of infants, pregnant and lactating mothers as prescribed by the treating physician if the expected curative effect exceeds the risk of possible side effects.

    Dosing and Administration:

    Assign 1-2 drops to the affected eye (both eyes) every 4-6 hours.

    In severe infections, the drug is prescribed 2 drops every hour until a clinical effect is obtained,after which the dose of the drug is gradually reduced to the complete cessation of use.

    Side effects:

    Local allergic reactions: puffiness, itchy eyelids, conjunctival erythema.

    With prolonged use, it is possible to increase intraocular pressure (therefore, when using preparations containing glucocorticosteroids for more than 10 days, intraocular pressure should be measured regularly).

    With constant use for more than 3 months, cataracts and mycoses of the cornea can develop.

    Perhaps slowing down the regeneration process.

    Overdose:

    Overdose Symptoms are similar to adverse reactions (point keratitis, erythema, increased lacrimation, edema and itching of the eyelids).

    Treatment symptomatic with the subsequent cancellation of the drug.

    Interaction:

    If Tebronezon is used in conjunction with systemic aminoglycoside antibiotics or steroids, precautions should be taken to monitor their total serum concentration.

    Special instructions:

    During the treatment with the drug, it is forbidden to wear soft contact lenses. When using hard lenses, remove them before instillation and re-dress 15-20 minutes after instillation of the drug.

    The bottle must be closed after each use. Do not touch the tip of the pipette to the eye.

    Effect on the ability to drive transp. cf. and fur:Patients who temporarily lose visual clarity after application are not recommended to drive a car or work with complicated equipment, machines or any other complex equipment that requires a clear vision immediately after instillation of the drug.
    Form release / dosage:Eye drops.
    Packaging:

    In polyethylene bottles-droppers for 5 ml.

    Each bottle is placed in a labeled cardboard box with instructions for use.

    Storage conditions:

    Store at a temperature not higher than 25 ° C, in a dry place, protected from light, out of reach of children. Do not freeze.

    Shelf life:

    2 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015176 / 01
    Date of registration:27.04.2009
    The owner of the registration certificate:Cadil Pharmaceuticals Co., Ltd.Cadil Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspCADILA PHARMACEUTICALS LTD. CADILA PHARMACEUTICALS LTD. India
    Information update date: & nbsp07.01.2016
    Illustrated instructions
      Instructions
      Up